Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study. (May 2021)
- Record Type:
- Journal Article
- Title:
- Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study. (May 2021)
- Main Title:
- Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study
- Authors:
- Bresolin, Andrea
Faiella, Adriana
Garibaldi, Elisabetta
Munoz, Fernando
Cante, Domenico
Vavassori, Vittorio
Waskiewicz, Justina Magdalena
Girelli, Giuseppe
Avuzzi, Barbara
Villa, Elisa
Magli, Alessandro
Noris Chiorda, Barbara
Gatti, Marco
Ferella, Letizia
Maggio, Angelo
Landoni, Valeria
Aimonetto, Stefania
Sini, Carla
Rancati, Tiziana
Sanguineti, Giuseppe
Valdagni, Riccardo
Di Muzio, Nadia
Fiorino, Claudio
Cozzarini, Cesare - Abstract:
- Highlights: Patient-reported diarrhea and urgency were the most frequent acute symptoms in WPRT. Mild symptoms before radiotherapy are the major predictors. V46 < 80 cc is an efficient constraint in reducing the risk about below 20%. Abstract: Background and purpose: To assess bowel dose-volume relationships for acute patient-reported intestinal symptoms of patients treated with whole-pelvis intensity-modulated radiotherapy (WPRT) for prostate cancer. Materials and methods: Complete data of 415 patients enrolled in a multi institute, prospective trial (#NCT02803086) treated with radical (31%), adjuvant (33%) and salvage (36%) intent at a median dose to pelvic nodes/lymph-nodal area of 53 Gy were available. The most severe changes between baseline and radiotherapy mid-point/end toxicity assessed by Inflammatory Bowel Disease Questionnaire (only Bowel Domain) were considered (ΔIBDQ). The 25th percentile values of these score variations were set as endpoints. DVHs of bowel loops for patients with/without toxicity were compared for each endpoint, having excluded patients with baseline scores <5 (rate ranging between 2% and 7% according to the endpoint): the resulting best dosimetric predictors were combined with selected clinical parameters through multivariate logistic regression (MVA) to derive predictive models. Results: ΔIBDQ ranged between 0.2–1.5 points considering separately each IBDQ symptom. Only four symptoms (IBDQ1 = frequency, IBDQ5 = diarrhea, IBDQ17 = gas passage,Highlights: Patient-reported diarrhea and urgency were the most frequent acute symptoms in WPRT. Mild symptoms before radiotherapy are the major predictors. V46 < 80 cc is an efficient constraint in reducing the risk about below 20%. Abstract: Background and purpose: To assess bowel dose-volume relationships for acute patient-reported intestinal symptoms of patients treated with whole-pelvis intensity-modulated radiotherapy (WPRT) for prostate cancer. Materials and methods: Complete data of 415 patients enrolled in a multi institute, prospective trial (#NCT02803086) treated with radical (31%), adjuvant (33%) and salvage (36%) intent at a median dose to pelvic nodes/lymph-nodal area of 53 Gy were available. The most severe changes between baseline and radiotherapy mid-point/end toxicity assessed by Inflammatory Bowel Disease Questionnaire (only Bowel Domain) were considered (ΔIBDQ). The 25th percentile values of these score variations were set as endpoints. DVHs of bowel loops for patients with/without toxicity were compared for each endpoint, having excluded patients with baseline scores <5 (rate ranging between 2% and 7% according to the endpoint): the resulting best dosimetric predictors were combined with selected clinical parameters through multivariate logistic regression (MVA) to derive predictive models. Results: ΔIBDQ ranged between 0.2–1.5 points considering separately each IBDQ symptom. Only four symptoms (IBDQ1 = frequency, IBDQ5 = diarrhea, IBDQ17 = gas passage, IBDQ24 = urgency) showed a median worsening ≥ 1; DVH predicted the risk of worse symptoms for IBDQ5, IBDQ24 and overall Bowel Domain. At multivariable analysis DVHs (best cut-off: V46Gy ≥80 cc) and baseline scores (Odd-Ratio:0.35–0.65) were independently associated to the three end-points. The resulting models were reliable (H&L test: 0.453–0.956), well calibrated (calibration plot: slope = 0.922–1.069, R 2 = 0.725–0.875) and moderately discriminative (Area Under the Curve:0.628–0.669). A bootstrap-based validation confirmed their robustness. Conclusion: Constraining the bowel loops (V46 < 80 cc) may reduce the risk of several moderate intestinal symptoms, with a much greater impact for patients with lower IBDQ baseline scores. … (more)
- Is Part Of:
- Radiotherapy and oncology. Volume 158(2021)
- Journal:
- Radiotherapy and oncology
- Issue:
- Volume 158(2021)
- Issue Display:
- Volume 158, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 158
- Issue:
- 2021
- Issue Sort Value:
- 2021-0158-2021-0000
- Page Start:
- 74
- Page End:
- 82
- Publication Date:
- 2021-05
- Subjects:
- Acute bowel toxicity -- Diarrhea -- Predictive models -- Prostate cancer -- Dose-volume effect
WPRT whole-pelvis radiotherapy -- QoL quality of life -- PRO patient-reported outcomes -- IBDQ inflammatory bowel disease questionnaire -- IBDQ-B IBDQ bowel domain -- IBDQ-E IBDQ emotional domain -- IBDQ-Sy IBDQ systemic domain -- IBDQ-So IBDQ social domain -- ΔIBDQ5 maximum variation of the "loose bowel movement" IBDQ item -- ΔIBDQ24 maximum variation of the "urgency" IBDQ item -- ΔIBDQ-B maximum variation of the mean score relative to the IBDQ bowel domain -- BMI body mass index -- DVH dose-volume histogram -- IHU-WPRT TOX intestinal, hematologic and urinary toxicity from whole-pelvis radiotherapy cohort study -- EPQ-R Eysenck personality questionnaire (revised) -- RT radiotherapy -- PB-PTV prostatic bed planning target volume -- LN-PTV lymph nodes planning target volume -- UVA univariable logistic regression analysis -- MVA multivariable logistic regression analysis -- H&L Hosmer and Lemeshow test -- Vx volume (cm3) of small bowel loops receiving x Gy -- PORT post-prostatectomy radiotherapy -- RAD radical radiotherapy
Oncology -- Periodicals
Radiotherapy -- Periodicals
Tumors -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- radiotherapy -- Periodicals
Radiotherapy -- Periodicals
Radiothérapie -- Périodiques
Cancérologie -- Périodiques
Tumeurs -- Périodiques
Electronic journals
616.9940642 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01678140 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01678140 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01678140 ↗
http://www.estro.org/ ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/radiotherapy-and-oncology/ ↗ - DOI:
- 10.1016/j.radonc.2021.02.026 ↗
- Languages:
- English
- ISSNs:
- 0167-8140
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7240.790000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22684.xml